testosterone 1.62% gel for Testicular Hypogonadism
Study Summary
This trial is testing whether testosterone replacement can help with cancer-related fatigue in older men who have low testosterone levels.
- Testicular Hypogonadism
- Cancer
- Fatigue
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
Are we still able to enroll patients in this clinical trial?
"According to the website clinicaltrials.gov, this particular trial is still looking for participants and is currently in the recruitment stage. This trial was first posted on 1/12/2021 and was last edited on 3/9/2022."
Has research been published on 1.62% testosterone gel in the past?
"At this time, there are a total of 32 active studies on testosterone 1.62% gel with 5 being in Phase 3. Most investigations for testosterone 1.62% gel take place in Houston, Texas; however, there are 158 locations worldwide conducting clinical trials for this medication."
Could you please list the potential side effects of using testosterone 1.62% gel?
"Although there is some evidence indicating that testosterone 1.62% gel is safe, it only received a score of 2 because this is a Phase 2 trial with no data supporting efficacy."
What is the general purpose of testosterone 1.62% gel?
"Patients suffering from hypogonadotropic hypogonadism, post-menopausal women 1 to 5 years after menopause, and those that have had an orchidectomy can all be treated with testosterone 1.62% gel."
How many participants are being welcomed into this research?
"That is correct. According to the listings on clinicaltrials.gov, this study is still looking for participants. The posting date was 1/12/2021 with a most recent update on 3/9/2022. They are aiming to enroll 230 total patients from 3 different locations."